Last update May 16, 2023

Tralokinumab

Low Risk

Possibly safe. Probably compatible. Mild risk possible. Follow up recommended. Read the Comment.

It is a monoclonal antibody directed against interleukin-13 that is used in the treatment of moderate to severe atopic dermatitis. Weekly subcutaneous administration.

At the date of the last update we did not find any published data on its excretion in breast milk.

It´s very high molecular weight (> 100,000 Da) makes it very unlikely to pass into breast milk in a significant quantity, since molecules of more than 800 - 1,000 Da do not pass into breast milk.

Due to its protein nature, it is inactivated in the gastrointestinal tract without being absorbed (practically nil oral bioavailability) and this hinders or prevents its passage into the infant´s plasma from ingested breast milk, except for premature infants and during the immediate neonatal period when there might be a greater intestinal permeability.

Alternatives

We do not have alternatives for Tralokinumab.

Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.

Jose Maria Paricio, Founder & President of APILAM/e-Lactancia

Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.

Thank you for helping to protect and promote breastfeeding.

José María Paricio, founder of e-lactancia.

Other names

Tralokinumab in other languages or writings:

Groups

Tralokinumab belongs to these groups or families:

Tradenames

Main tradenames from several countries containing Tralokinumab in its composition:

Pharmacokinetics

Variable Value Unit
Oral Bioavail. ≈ 0 %
Molecular weight 147.000 daltons
VD 0.06 l/Kg
Tmax 120 - 190 hours
528 hours

References

  1. EMA. Tralokinumab Ficha técnica. 2021 Full text (in our servers)
  2. Leo. Tralokinumab. Drug Summary. 2021 Full text (in our servers)

Total visits

469

Help us improve this entry

How to cite this entry

Do you need more information or did not found what you were looking for?

   Write us at elactancia.org@gmail.com

e-lactancia is a resource recommended by El Parto Es Nuestro of Spain

Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM